Article thumbnail

The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms

By Amy M Egras and Elena M Umland


Vasomotor symptoms (VMS) are among the most bothersome complaints of postmenopausal women. To date, the most widely studied and effective treatment for VMS is hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for treatment. However, over the years, additional estrogen formulations have been developed including transdermal patches; vaginal rings, creams, and tablets; and injectable preparations. Two newer formulations are transdermal estrogen spray and estradiol topical emulsion. This review evaluates the current literature assessing the use of these two newer formulations for the treatment of VMS associated with menopause

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate.
  2. American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Vasomotor symptoms. Obstet Gynecol.
  3. (2008). and partner transfer of estradiol from a topical emulsion. Pharmaco Therapy.
  4. (1989). Biosynthesis and physiologic effects of estrogen and pathophysiologic effects of estrogen deficiency: a review. Am J Obstet Gynecol.
  5. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
  6. (2004). Considerations in the choice of oral vs transdermal hormone therapy: a review. J Reprod Med.
  7. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
  8. Health care seeking and treatment for menopausal symptoms in the United States.
  9. (2008). Low-dose estradiol spray to treat vasomotor symptoms. Obstet Gynecol.
  10. (2008). Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women:
  11. Menopause Society. Treatment of menopauseassociated vasomotor symptoms: position statement of The North American Menopause Society.
  12. of Health. NIH state-of-the-science conference statement on management of menopause-related symptoms.
  13. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev.
  14. Pharmacology of estrogens and progestogens: influence of different routes of administration.
  15. (2007). Product Information: EVAMISTTM transdermal spray, estradiol transdermal spray.
  16. (2005). Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes.
  17. (1999). Reduced thermoregulatory null zone in postmenopausal women with hot flashes.
  18. The effects of skin-to-skin contact, application site washing, and s unscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray.
  19. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors.